Observational Study of Metabolic Features in Melanoma
This observational study aims to understand how the metabolism (the way your body uses energy) of melanoma (skin cancer) tumors is linked to how the cancer progresses. Researchers will collect melanoma tissue during surgery (biopsy or removal) and analyze it to see its metabolic features. Some participants will receive a special type of sugar called [U-13C]glucose to help track these metabolic processes. The study will then compare these metabolic findings with your clinical information, such as survival and if the cancer spreads. The main goal is to measure how glucose (sugar) is used in a process called the TCA cycle, and this will be assessed over 5 years. You may be able to join if you are over 18, have melanoma needing surgery, and do not have poorly controlled diabetes.
- Study design
- This is an observational study involving 400 participants. It is a single-center study designed to look at metabolic features in melanoma tumors.
- What's involved
- You would provide a melanoma tissue sample during your surgical biopsy or excision. A subset of patients will also receive [U-13C]glucose infusions.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, Glucose Utilisation in the TCA cycle, will be measured at 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jennifer Gill, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Glucose Utilisation in the TCA cycle5 years
In patients receiving a \[U-13C\]Glucose infusion, assess glucose utilization in the TCA cycle by melanoma tumors (defined as fractional enrichment of 13C-label in TCA metabolites)